2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T5c2,To evaluate glycemic metrics and insulin delivery during real-world use of the MiniMed 780G (MM780G) system on days when users did not administer boluses. Global CareLink personal data of consenting MM780G users (N = 369,467) uploaded from 2 January 2020 to 31 March 2025 were analyzed. Among these individuals, 54,553 users experienced ≥10 days without any user-initiated boluses. Evaluated key metrics included time in range (TIR; 70-180 mg/dL), time below range (TBR; <70 mg/dL), time above range (>180 mg/dL), the glucose management indicator (GMI), and total insulin delivered. These were analyzed for the overall population who did not initiate boluses and for those who used and did not use recommended optimal settings (ROS; defined as a 100 mg/dL glucose target and a 2-h active insulin time). Subgroup analyses were conducted by age (≤15 or >15 years) and diabetes type (type 1 or 2). On days when boluses were missed, ROS users had a mean sensor glucose (SG) of 149.2 mg/dL, with mean TIR, TBR, and GMI of 76.3%, 0.8%, and 6.9%, respectively, whereas non-ROS users had a mean SG of 159.7 mg/dL with mean TIR, TBR, and GMI of 69.3%, 0.9%, and 7.1%, respectively. ROS use was associated with more individuals achieving consensus TIR, TBR, and GMI goals. These data demonstrate effective glycemic control with the MM780G system on days when some users did not initiate boluses. A greater proportion of real-world users achieved glycemic goals when ROS were used.31:T835, OBJECTIVE To evaluate glycemic metrics and insulin delivery during real-world use of the MiniMed 780G (MM780G) system on days when users did not administer boluses. RESEARCH DESIGN AND METHODS Global CareLink personal data of consenting MM780G users (N = 369,467) uploaded from 2 January 2020 to 31 March 2025 were analyzed. Among these individuals, 54,553 users experienced ≥10 days without any user-initiated boluses. Evaluated key metrics included time in range (TIR; 70–180 mg/dL), time below range (TBR; <70 mg/dL), time above range (>180 mg/dL), the glucose management indicator (GMI), and total insulin delivered. These were analyzed for the overall population who did not initiate boluses and for those who used and did not use recommended optimal settings (ROS; defined as a 100 mg/dL glucose target and a 2-h active insulin time). Subgroup analyses were conducted by age (≤15 or >15 years) and diabetes type (type 1 or 2). RESULTS On days when boluses were missed, ROS users had a mean sensor glucose (SG) of 149.2 mg/dL, with mean TIR, TBR, and GMI of 76.3%, 0.8%, and 6.9%, respectively, whereas non-ROS users had a mean SG of 159.7 mg/dL with mean TIR, TBR, and GMI of 69.3%, 0.9%, and 7.1%, respectively. ROS use was associated with more individuals achieving consensus TIR, TBR, and GMI goals. CONCLUSIONS These data demonstrate effective glycemic control with the MM780G system on days when some users did not initiate boluses. A greater proportion of real-world users achieved glycemic goals when ROS were used. 32:T69f,Insulin resistance increases after the first trimester of pregnancy, leading to glycaemic challenges for women with pregestational type 1 diabetes or type 2 diabetes. Additionally, insulin resistance can promote hyperglycaemia in pregnant women without type 1 diabetes or type 2 diabetes, who develop gestational diabetes. Although most (>95%) women with diabetes deliver healthy babies, maternal dysglycaemia can have consequences for the mother and child, including prenatal, perinatal, immediate, and long-term postnatal complications. Diabetes technologies, such as continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems can aid in optimising glycaemia outside of pregnancy. These novel technologies have not been extensively tested in large randomised controlled trials before and during pregnancy. However, compelling data report the benefits of CGM in type 1 diabetes, and increasing data report on AID systems in pregnancies complicated by type 1 diabetes. Appropriate CGM glucose thresholds for the diagnosis of gestational diabetes and the recommended time in range treatment targets for the routine management of gestational diabetes and type 2 diabetes still need to be determined. The recommendations in this Consensus Statement emphasise the value of CGM during preconception and pregnancy for women with pregestational type 1 diabetes in reducing pregnancy complications. Recommendations also include the use of AID systems in women with pregestational type 1 diabetes to improve glycaemic management during preconception, during pregnancy and delivery, and in the postpartum period. This Consensus Statement has been endorsed by 24 societies and groups.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Automated Insulin Delivery: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Automated Insulin Delivery (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Automated%20Insulin%20Delivery\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Automated Insulin Delivery\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Automated%20Insulin%20Delivery\"}]}}"}}]],["$","$L2f",null,{"title":"Automated Insulin Delivery: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Automated Insulin Delivery — concise summaries and practical next steps.","papers":[{"doi":"10.2337/dc26-0692","pmid":"42482329","title":"Effects of Menstrual Cycle on Insulin Sensitivity in Type 1 Diabetes: An Observational Study of Individuals Using an Automated Insulin Delivery System","journal_title":"Diabetes Care","journal_issn":"0149-5992","published_at":"2026-07-22T00:00:00.000Z","url":"https://doi.org/10.2337/dc26-0692","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:19.213Z","updated_at":"2026-07-31T13:37:19.213Z","tags":[{"paper_doi":"10.2337/dc26-0692","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"modality","value":"Automated Insulin Delivery","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"modality","value":"Continuous Glucose Monitoring","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"sample_size","value":"n=77","value_numeric":77},{"paper_doi":"10.2337/dc26-0692","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"study_design","value":"Observational Study","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"warning","value":"Cycle phases were self-reported by participants and not confirmed with hormonal measurements, which may introduce misclassification of cycle phase.","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"warning","value":"The Bayesian state-space model used to estimate insulin sensitivity is a novel, non-standard approach; results should be interpreted with awareness of modeling assumptions.","value_numeric":null},{"paper_doi":"10.2337/dc26-0692","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — while findings are clinically meaningful, current AID systems and guidelines have not yet incorporated these recommendations.","value_numeric":null}],"summaries":{"what_studied":"This decentralized observational study evaluated how menstrual cycle phase affects insulin sensitivity, insulin requirements, and glycemic outcomes in 77 menstruating adults with type 1 diabetes using automated insulin delivery (AID) systems, across 380 real-world menstrual cycles.","key_result":"Insulin dose and carbohydrate intake peaked in the luteal phase, with higher mean glucose and reduced time in range. Model-derived insulin sensitivity was +2.6% higher in the early follicular phase (CrI 0.3–5.0) vs. −2.6% in the midluteal phase (CrI −5.2 to −0.1); 84.7% of participants followed this population-level trend, but substantial interindividual variation was observed.","limitations":"Observational design with self-reported, real-world data limits causal inference; cycle phases were self-reported rather than confirmed by hormonal assays; interindividual heterogeneity means population-level trends may not apply to all patients.","practice_takeaway":"Clinicians managing type 1 diabetes in menstruating patients should anticipate increased insulin needs and worsened glycemic control during the luteal phase. Current AID systems and guidelines do not yet account for this cycle-phase variation, suggesting a gap worth addressing in personalized diabetes management."}},{"doi":"10.1177/15209156261456826","pmid":"42338327","title":"Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes","journal_title":"Diabetes Technology & Therapeutics","journal_issn":"1520-9156","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1177/15209156261456826","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-03T13:38:58.858Z","updated_at":"2026-07-03T13:38:58.858Z","tags":[{"paper_doi":"10.1177/15209156261456826","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"brand","value":"Omnipod 5","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"modality","value":"Automated Insulin Delivery","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"sample_size","value":"n=176405","value_numeric":176405},{"paper_doi":"10.1177/15209156261456826","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — findings are observational and driven by logistic regression, not a randomized trial; however, the large sample size and specific actionable thresholds give the results clinical weight.","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"warning","value":"The study population is limited to Insulet device users in the US and Europe; results may not generalize to other AID systems or global populations.","value_numeric":null},{"paper_doi":"10.1177/15209156261456826","tag_type":"warning","value":"The very low adoption rates of optimized settings (especially in pediatric users, 1.4%) suggest potential selection bias within the optimized-settings subgroup.","value_numeric":null}],"summaries":{"what_studied":"This retrospective real-world analysis identified programmable device settings and user behaviors associated with achieving >70% time in range (TIR; 70–180 mg/dL) in 176,405 Omnipod 5 AID users aged ≥2 years with type 1 diabetes in the US and Europe (data from Q1 2025).","key_result":"Optimized settings (110 mg/dL glucose target, I:C ratio ≤350/TDD, CF ≤1500/TDD) combined with ≥90% time in Automated Mode and ≥3 boluses/day yielded median TIR of 77% (adults) and 78% (pediatric users), vs. 66% and 62% for overall users, respectively — with hypoglycemia remaining low across age groups. Only 7.9% of adults and 1.4% of pediatric users applied all optimized criteria.","limitations":"Retrospective, observational design precludes causal inference. Only 7.9% of adults and 1.4% of pediatric users met all optimized criteria, limiting generalizability of the optimal-settings subgroup. Confounding by user motivation, diabetes education, or clinical support cannot be ruled out.","practice_takeaway":"Clinicians should target a 110 mg/dL glucose target, set I:C ratio ≤350/TDD, and CF ≤1500/TDD, while coaching patients to stay in Automated Mode ≥90% of the time and bolus ≥3 times per day to maximize TIR with the Omnipod 5 system. Very few users currently apply all these settings — this gap represents a clear, actionable opportunity for clinical intervention."}},{"doi":"10.1177/15209156261449884","pmid":"42165353","title":"Glycemic Concordance of Simplera Sync\n ™\n and Instinct\n ™\n Sensors in MiniMed\n ™\n 780G System Users: A Randomized Crossover Feasibility Study","journal_title":"Diabetes Technology & Therapeutics","journal_issn":"1520-9156","published_at":"2026-05-21T00:00:00.000Z","url":"https://doi.org/10.1177/15209156261449884","source_score":50,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-28T13:24:27.690Z","updated_at":"2026-05-28T13:24:27.690Z","tags":[{"paper_doi":"10.1177/15209156261449884","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"brand","value":"Instinct","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"brand","value":"MiniMed 780G","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"brand","value":"Simplera Sync","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"modality","value":"Automated Insulin Delivery","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"modality","value":"Continuous Glucose Monitor","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"sample_size","value":"n=23","value_numeric":23},{"paper_doi":"10.1177/15209156261449884","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"study_design","value":"Randomized Crossover Trial","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"warning","value":"The 'Instinct' sensor is not widely referenced in prior literature; clinicians should verify availability and regulatory status in their region.","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"warning","value":"The study was single-center, which may limit generalizability to broader populations or clinical settings.","value_numeric":null},{"paper_doi":"10.1177/15209156261449884","tag_type":"warning","value":"Very small sample size (n=23) makes this a feasibility study; results should be interpreted with caution pending larger confirmatory trials.","value_numeric":null}],"summaries":{"what_studied":"This single-center, randomized crossover feasibility study evaluated whether Simplera Sync™ and Instinct™ CGM sensors are interchangeable in adults with type 1 diabetes using the MiniMed™ 780G automated insulin delivery (AID) system, with each sensor worn for 6 weeks in sequence.","key_result":"Noninferiority in TIR (70–180 mg/dL) was met: TIR was 80.6% with Simplera Sync vs. 79.1% with Instinct (mean difference 1.5%; 95% CI: 0.18–2.79%). HbA1c was 6.8% and 6.7% at end of each period, respectively. No serious adverse events related to sensor use were reported.","limitations":"Very small sample (n=23 completers) limits generalizability; single-center design may reduce external validity; feasibility study was not powered to detect subtle differences in secondary outcomes.","practice_takeaway":"Clinicians can reassure patients on the MiniMed 780G that switching between Simplera Sync and Instinct sensors does not meaningfully affect glycemic control. The AID algorithm appears to be the primary driver of outcomes, not the specific sensor used."}},{"doi":"10.2337/dc25-2124","pmid":"41498529","title":"MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses","journal_title":"Diabetes Care","journal_issn":"0149-5992","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.2337/dc25-2124","source_score":50,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.2337/dc25-2124","days":"7","issn":"0149-5992","rank":"5","field":"Clinical Medicine","score":"50","category":"Endocrinology & Metabolism","categories":["Endocrinology & Metabolism"],"_categories":["Endocrinology & Metabolism"]},"pubmed":{"doi":"10.2337/dc25-2124","title":"MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses.","journal":"Diabetes care","methods":"","results":"On days when boluses were missed, ROS users had a mean sensor glucose (SG) of 149.2 mg/dL, with mean TIR, TBR, and GMI of 76.3%, 0.8%, and 6.9%, respectively, whereas non-ROS users had a mean SG of 159.7 mg/dL with mean TIR, TBR, and GMI of 69.3%, 0.9%, and 7.1%, respectively. ROS use was associated with more individuals achieving consensus TIR, TBR, and GMI goals.","abstract":"$30","keywords":[],"pubmed_id":"41498529","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.2337/dc25-2124","URL":"https://doi.org/10.2337/dc25-2124","ISSN":["0149-5992","1935-5548"],"link":[{"URL":"https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2124/852772/dc252124.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2124/852772/dc252124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses"],"author":[{"given":"Fang","family":"Niu","sequence":"first","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]},{"given":"Margaret","family":"Liu","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]},{"given":"Caroline","family":"Yovanovich","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]},{"given":"Robert A.","family":"Vigersky","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]},{"given":"John J.","family":"Shin","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]},{"given":"Jennifer J.F.","family":"McVean","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, CA"}]}],"funder":[{"name":"Medtronic Diabetes"}],"issued":{"date-parts":[[2026,1,7]]},"member":"1167","prefix":"10.2337","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T13:46:35Z","timestamp":1767793595000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T16:12:48Z","timestamp":1767802368473,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://www.diabetesjournals.org/journals/pages/license","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://diabetesjournals.org/care/article/doi/10.2337/dc25-2124/164061/MiniMed-780G-Advanced-Hybrid-Closed-Loop-System"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T13:46:36Z","timestamp":1767793596000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"0149-5992"},{"type":"electronic","value":"1935-5548"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Diabetes Association","reference":null,"short-title":[],"update-policy":"https://doi.org/10.2337/ada-journal-policies","article-number":"dc252124","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Diabetes Care"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.2337/dc25-2124","is_oa":true,"title":"MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2124/852772/dc252124.pdf","pmh_id":null,"url_for_pdf":"https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-2124/852772/dc252124.pdf","url_for_landing_page":"https://doi.org/10.2337/dc25-2124"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.2337/dc25-2124","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"brand","value":"MiniMed 780G","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"condition","value":"Type 1 Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"condition","value":"Type 2 Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"modality","value":"Automated Insulin Delivery","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"sample_size","value":"n=369,467","value_numeric":369467},{"paper_doi":"10.2337/dc25-2124","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"warning","value":"Design classification is inferred from an observational device-data analysis and may not match the authors’ stated design.","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"warning","value":"It is unclear whether reported metrics reflect all users with any missed-bolus days or only those with ≥10 such days.","value_numeric":null},{"paper_doi":"10.2337/dc25-2124","tag_type":"warning","value":"No numeric counts were provided for the proportion achieving consensus goals; subgroup results by age and diabetes type were mentioned but not quantified.","value_numeric":null}],"summaries":{"what_studied":"Real-world device data from MiniMed 780G users (n=369,467) uploaded 2 Jan 2020–31 Mar 2025; 54,553 users had ≥10 days without any user-initiated boluses. Glycemic metrics on missed-bolus days were compared between users with recommended optimal settings (ROS: 100 mg/dL target, 2-h active insulin time) and those without; subgroup analyses by age (≤15 vs >15 years) and diabetes type (1 vs 2) were described.","key_result":"On missed-bolus days, ROS users had mean sensor glucose 149.2 mg/dL, TIR 76.3%, TBR 0.8%, and GMI 6.9%; non-ROS users had mean sensor glucose 159.7 mg/dL, TIR 69.3%, TBR 0.9%, and GMI 7.1%. More ROS users achieved consensus TIR, TBR, and GMI goals (no counts provided).","practice_takeaway":"On days without user-initiated boluses, MiniMed 780G maintained good glycemic control, with better metrics when ROS (100 mg/dL target, 2-h active insulin time) were used. Using these settings was associated with higher TIR and lower mean glucose on missed-bolus days."}},{"doi":"10.1016/s2213-8587(25)00335-3","pmid":"41421368","title":"Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement","journal_title":"The Lancet Diabetes & Endocrinology","journal_issn":"2213-8587","published_at":"2025-12-21T00:00:00.000Z","url":"https://doi.org/10.1016/s2213-8587(25)00335-3","source_score":115,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-19","doi":"10.1016/s2213-8587(25)00335-3","days":"30","issn":"2213-8587","rank":"6","field":"Clinical Medicine","score":"115","category":"Endocrinology & Metabolism","categories":["Endocrinology & Metabolism"],"_categories":["Endocrinology & Metabolism"]},"pubmed":{"doi":"10.1016/S2213-8587(25)00335-3","title":"Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement.","journal":"The lancet. Diabetes & endocrinology","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41421368","conclusions":"","publication_date":"2025-12-21T00:00:00"},"crossref":{"DOI":"10.1016/s2213-8587(25)00335-3","URL":"https://doi.org/10.1016/s2213-8587(25)00335-3","ISSN":["2213-8587"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S2213858725003353?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S2213858725003353?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"157-177","type":"journal-article","issue":"2","score":1,"title":["Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement"],"author":[{"given":"Katrien","family":"Benhalima","sequence":"first","affiliation":[]},{"given":"Celeste","family":"Durnwald","sequence":"additional","affiliation":[]},{"given":"Arianne","family":"Sweeting","sequence":"additional","affiliation":[]},{"given":"Dawn","family":"Adams","sequence":"additional","affiliation":[]},{"given":"Ananta","family":"Addala","sequence":"additional","affiliation":[]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[]},{"given":"Richard M","family":"Bergenstal","sequence":"additional","affiliation":[]},{"given":"Anders","family":"Carlson","sequence":"additional","affiliation":[]},{"given":"Lois E","family":"Donovan","sequence":"additional","affiliation":[]},{"given":"Denise","family":"Reis Franco","sequence":"additional","affiliation":[]},{"given":"Julie","family":"Heverly","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[]},{"given":"Anne-Beatrice","family":"Kihara","sequence":"additional","affiliation":[]},{"given":"Naomi","family":"Levitt","sequence":"additional","affiliation":[]},{"given":"Carol J","family":"Levy","sequence":"additional","affiliation":[]},{"given":"Mareda","family":"Lewer","sequence":"additional","affiliation":[]},{"given":"Elisabeth","family":"Mathiesen","sequence":"additional","affiliation":[]},{"given":"Helen R","family":"Murphy","sequence":"additional","affiliation":[]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[]},{"given":"Sarit","family":"Polsky","sequence":"additional","affiliation":[]},{"given":"Uma","family":"Ram","sequence":"additional","affiliation":[]},{"given":"David","family":"Simmons","sequence":"additional","affiliation":[]},{"given":"Jennifer M","family":"Yamamoto","sequence":"additional","affiliation":[]},{"given":"Ádám G","family":"Tabák","sequence":"additional","affiliation":[]},{"given":"Denice","family":"Feig","sequence":"additional","affiliation":[]},{"given":"Eleanor M","family":"Scott","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,2]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"14","created":{"date-time":"2025-12-17T23:36:35Z","timestamp":1766014595000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2026-01-12T16:33:56Z","timestamp":1768235636288,"date-parts":[[2026,1,12]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000,"date-parts":[[2026,2,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S2213858725003353"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement"},{"name":"journaltitle","label":"Journal Title","value":"The Lancet Diabetes & Endocrinology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/S2213-8587(25)00335-3"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2026-01-12T13:09:51Z","timestamp":1768223391000,"date-parts":[[2026,1,12]]},"issn-type":[{"type":"print","value":"2213-8587"}],"published":{"date-parts":[[2026,2]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/S0140-6736(17)32400-5","key":"10.1016/S2213-8587(25)00335-3_bib1","year":"2017","issue":null,"author":"Feig","volume":"390","first-page":"2347","unstructured":null,"article-title":"Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(23)00116-X","key":"10.1016/S2213-8587(25)00335-3_bib2","year":"2023","issue":null,"author":"Benhalima","volume":"11","first-page":"490","unstructured":null,"article-title":"Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(20)30406-X","key":"10.1016/S2213-8587(25)00335-3_bib3","year":"2021","issue":null,"author":"Murphy","volume":"9","first-page":"153","unstructured":null,"article-title":"Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa0902430","key":"10.1016/S2213-8587(25)00335-3_bib4","year":"2009","issue":null,"author":"Landon","volume":"361","first-page":"1339","unstructured":null,"article-title":"A multicenter, randomized trial of treatment for mild gestational diabetes","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.15999","key":"10.1016/S2213-8587(25)00335-3_bib5","year":"2024","issue":"suppl 7","author":"Benhalima","volume":"26","first-page":"74","unstructured":null,"article-title":"Use of continuous glucose monitoring and hybrid closed-loop therapy in pregnancy","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.3389/fgwh.2022.818856","key":"10.1016/S2213-8587(25)00335-3_bib6","year":"2022","issue":null,"author":"Gribble","volume":"3","first-page":null,"unstructured":null,"article-title":"Effective communication about pregnancy, birth, lactation, breastfeeding and newborn care: the importance of sexed language","journal-title":"Front Glob Womens Health","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pmed.1004390","key":"10.1016/S2213-8587(25)00335-3_bib7","year":"2024","issue":null,"author":"Logullo","volume":"21","first-page":null,"unstructured":null,"article-title":"ACcurate COnsensus Reporting Document (ACCORD) explanation and elaboration: guidance and examples to support reporting consensus methods","journal-title":"PLoS Med","doi-asserted-by":"crossref"},{"DOI":"10.2105/AJPH.62.3.337","key":"10.1016/S2213-8587(25)00335-3_bib8","year":"1972","issue":null,"author":"Van de Ven","volume":"62","first-page":"337","unstructured":null,"article-title":"The nominal group as a research instrument for exploratory health studies","journal-title":"Am J Public Health","doi-asserted-by":"crossref"},{"DOI":"10.2337/dci20-0053","key":"10.1016/S2213-8587(25)00335-3_bib9","year":"2021","issue":null,"author":"Hill-Briggs","volume":"44","first-page":"258","unstructured":null,"article-title":"Social determinants of health and diabetes: a scientific review","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib10","year":null,"issue":null,"author":"Solar","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2337/dci20-0060","key":"10.1016/S2213-8587(25)00335-3_bib11","year":"2021","issue":null,"author":"Ogunwole","volume":"44","first-page":"11","unstructured":null,"article-title":"Social determinants of health and structural inequities—root causes of diabetes disparities","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib12","year":"2025","issue":null,"author":"Conway","volume":"9","first-page":null,"unstructured":null,"article-title":"Disparities in diabetes technology uptake in youth and young adults with type 1 diabetes: a global perspective","journal-title":"J Endocr Soc","doi-asserted-by":null},{"DOI":"10.1136/bmjph-2024-001128","key":"10.1016/S2213-8587(25)00335-3_bib13","year":"2025","issue":null,"author":"Ewen","volume":"3","first-page":null,"unstructured":null,"article-title":"Availability, prices and affordability of self-monitoring blood glucose devices: surveys in six low-income and middle-income countries","journal-title":"BMJ Public Health","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc20-0257","key":"10.1016/S2213-8587(25)00335-3_bib14","year":"2021","issue":null,"author":"Addala","volume":"44","first-page":"133","unstructured":null,"article-title":"A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1210/clinem/dgaa236","key":"10.1016/S2213-8587(25)00335-3_bib15","year":"2020","issue":null,"author":"Agarwal","volume":"105","first-page":"e2960","unstructured":null,"article-title":"Racial-ethnic inequity in young adults with type 1 diabetes","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2014-1774","key":"10.1016/S2213-8587(25)00335-3_bib16","year":"2015","issue":null,"author":"Willi","volume":"135","first-page":"424","unstructured":null,"article-title":"Racial-ethnic disparities in management and outcomes among children with type 1 diabetes","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc18-0724","key":"10.1016/S2213-8587(25)00335-3_bib17","year":"2018","issue":null,"author":"Auzanneau","volume":"41","first-page":"2517","unstructured":null,"article-title":"Area deprivation and regional disparities in treatment and outcome quality of 29,284 pediatric patients with type 1 diabetes in Germany: a cross-sectional multicenter DPV analysis","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ecl.2016.01.002","key":"10.1016/S2213-8587(25)00335-3_bib18","year":"2016","issue":null,"author":"Lado","volume":"45","first-page":"453","unstructured":null,"article-title":"Racial and ethnic disparities in the incidence, treatment, and outcomes of youth with type 1 diabetes","journal-title":"Endocrinol Metab Clin North Am","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc20-1663","key":"10.1016/S2213-8587(25)00335-3_bib19","year":"2021","issue":null,"author":"Lai","volume":"44","first-page":"255","unstructured":null,"article-title":"Racial and ethnic disparities in rates of continuous glucose monitor initiation and continued use in children with type 1 diabetes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1399-5448.2011.00766.x","key":"10.1016/S2213-8587(25)00335-3_bib20","year":"2011","issue":null,"author":"Valenzuela","volume":"12","first-page":"696","unstructured":null,"article-title":"Prescribed regimen intensity in diverse youth with type 1 diabetes: role of family and provider perceptions","journal-title":"Pediatr Diabetes","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2023.8881","key":"10.1016/S2213-8587(25)00335-3_bib21","year":"2023","issue":null,"author":"Addala","volume":"6","first-page":null,"unstructured":null,"article-title":"Disparities in hemoglobin A1c levels in the first year after diagnosis among youths with type 1 diabetes offered continuous glucose monitoring","journal-title":"JAMA Netw Open","doi-asserted-by":"crossref"},{"DOI":"10.1007/BF00258304","key":"10.1016/S2213-8587(25)00335-3_bib22","year":"1980","issue":null,"author":"Fisher","volume":"19","first-page":"15","unstructured":null,"article-title":"The insulin response to glucose infusion in normal human pregnancy","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1016/0002-9378(90)91306-W","key":"10.1016/S2213-8587(25)00335-3_bib23","year":"1990","issue":null,"author":"Buchanan","volume":"162","first-page":"1008","unstructured":null,"article-title":"Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.2337/diab.34.4.380","key":"10.1016/S2213-8587(25)00335-3_bib24","year":"1985","issue":null,"author":"Ryan","volume":"34","first-page":"380","unstructured":null,"article-title":"Insulin action during pregnancy. Studies with the euglycemic clamp technique","journal-title":"Diabetes","doi-asserted-by":"crossref"},{"DOI":"10.1016/0002-9378(91)90012-G","key":"10.1016/S2213-8587(25)00335-3_bib25","year":"1991","issue":null,"author":"Catalano","volume":"165","first-page":"1667","unstructured":null,"article-title":"Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.14743","key":"10.1016/S2213-8587(25)00335-3_bib26","year":"2022","issue":null,"author":"Diguisto","volume":"39","first-page":null,"unstructured":null,"article-title":"A study of diabetic ketoacidosis in the pregnant population in the United Kingdom: investigating the incidence, aetiology, management and outcomes","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib27","year":"2022","issue":null,"author":"Villavicencio","volume":"8","first-page":"221","unstructured":null,"article-title":"Diabetic ketoacidosis complicating gestational diabetes mellitus","journal-title":"AACE Clin Case Rep","doi-asserted-by":null},{"DOI":"10.1089/dia.2025.0300","key":"10.1016/S2213-8587(25)00335-3_bib28","year":"2025","issue":null,"author":"Durnwald","volume":null,"first-page":null,"unstructured":null,"article-title":"Continuous ketone monitoring in pregnancy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib29","year":"2025","issue":"suppl 1","author":null,"volume":"48","first-page":"s306","unstructured":null,"article-title":"15. Management of diabetes in pregnancy: standards of care in diabetes—2025","journal-title":"Diabetes Care","doi-asserted-by":null},{"DOI":"10.3390/nu15020323","key":"10.1016/S2213-8587(25)00335-3_bib30","year":"2023","issue":null,"author":"Dingena","volume":"15","first-page":"323","unstructured":null,"article-title":"Nutritional and exercise-focused lifestyle interventions and glycemic control in women with diabetes in pregnancy: a systematic review and meta-analysis of randomized clinical trials","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc18-0102","key":"10.1016/S2213-8587(25)00335-3_bib31","year":"2018","issue":null,"author":"Yamamoto","volume":"41","first-page":"1346","unstructured":null,"article-title":"Gestational diabetes mellitus and diet: a systematic review and meta-analysis of randomized controlled trials examining the impact of modified dietary interventions on maternal glucose control and neonatal birth weight","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib32","year":"2017","issue":null,"author":"Brown","volume":"6","first-page":null,"unstructured":null,"article-title":"Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1002/osp4.283","key":"10.1016/S2213-8587(25)00335-3_bib33","year":"2018","issue":null,"author":"Cremona","volume":"4","first-page":"455","unstructured":null,"article-title":"Effect of exercise modality on markers of insulin sensitivity and blood glucose control in pregnancies complicated with gestational diabetes mellitus: a systematic review","journal-title":"Obes Sci Pract","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000005669","key":"10.1016/S2213-8587(25)00335-3_bib34","year":"2024","issue":null,"author":"Battarbee","volume":"144","first-page":"649","unstructured":null,"article-title":"Continuous glucose monitoring for diabetes management during pregnancy: evidence, practical tips, and common pitfalls","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1177/193229681300700234","key":"10.1016/S2213-8587(25)00335-3_bib35","year":"2013","issue":null,"author":"Bergenstal","volume":"7","first-page":"562","unstructured":null,"article-title":"Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2024.0107","key":"10.1016/S2213-8587(25)00335-3_bib36","year":"2024","issue":null,"author":"Simonson","volume":"26","first-page":"814","unstructured":null,"article-title":"Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dci19-0028","key":"10.1016/S2213-8587(25)00335-3_bib37","year":"2019","issue":null,"author":"Battelino","volume":"42","first-page":"1593","unstructured":null,"article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968251315459","key":"10.1016/S2213-8587(25)00335-3_bib38","year":"2025","issue":null,"author":"Eichenlaub","volume":null,"first-page":null,"unstructured":null,"article-title":"Performance of three continuous glucose monitoring systems in adults with type 1 diabetes","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc25-0129","key":"10.1016/S2213-8587(25)00335-3_bib39","year":"2025","issue":null,"author":"Freckmann","volume":"48","first-page":"1213","unstructured":null,"article-title":"A comparative analysis of glycemic metrics derived from three continuous glucose monitoring systems","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968241250357","key":"10.1016/S2213-8587(25)00335-3_bib40","year":"2024","issue":null,"author":"Klonoff","volume":"19","first-page":"1392","unstructured":null,"article-title":"Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.16153","key":"10.1016/S2213-8587(25)00335-3_bib41","year":"2025","issue":null,"author":"Mathieu","volume":"27","first-page":"1025","unstructured":null,"article-title":"Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—'eCGM’ compliance status","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.3390/healthcare12141438","key":"10.1016/S2213-8587(25)00335-3_bib42","year":"2024","issue":null,"author":"Grinberg","volume":"12","first-page":null,"unstructured":null,"article-title":"Assessing mental health conditions in women with gestational diabetes compared to healthy pregnant women","journal-title":"Healthcare","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eclinm.2021.101016","key":"10.1016/S2213-8587(25)00335-3_bib43","year":"2021","issue":null,"author":"Delanerolle","volume":"38","first-page":null,"unstructured":null,"article-title":"A systematic review and meta-analysis of gestational diabetes mellitus and mental health among BAME populations","journal-title":"eClinicalMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.deman.2024.100198","key":"10.1016/S2213-8587(25)00335-3_bib44","year":"2024","issue":null,"author":"Salimi","volume":"14","first-page":null,"unstructured":null,"article-title":"Prevalence of anxiety and depression among pregnant women with diabetes and their predictors","journal-title":"Diabetes Epidemiol Manag","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12888-024-05960-4","key":"10.1016/S2213-8587(25)00335-3_bib45","year":"2024","issue":null,"author":"Nazarpour","volume":"24","first-page":"511","unstructured":null,"article-title":"The relationship between quality of life and some mental problems in women with gestational diabetes mellitus (GDM): a cross-sectional study","journal-title":"BMC Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11892-022-01468-x","key":"10.1016/S2213-8587(25)00335-3_bib46","year":"2022","issue":null,"author":"Cobry","volume":"22","first-page":"283","unstructured":null,"article-title":"Friend or foe: a narrative review of the impact of diabetes technology on sleep","journal-title":"Curr Diab Rep","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2024.111596","key":"10.1016/S2213-8587(25)00335-3_bib47","year":"2024","issue":null,"author":"Lin","volume":"209","first-page":null,"unstructured":null,"article-title":"Relationships of hypoglycemia awareness, hypoglycemia beliefs, and continuous glucose monitoring glycemic profiles with anxiety and depression symptoms in adults with type 1 diabetes using continuous glucose monitoring systems","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2020.0666","key":"10.1016/S2213-8587(25)00335-3_bib48","year":"2021","issue":null,"author":"Gilbert","volume":"23","first-page":"s35","unstructured":null,"article-title":"Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the landmark study","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc14-1855","key":"10.1016/S2213-8587(25)00335-3_bib49","year":"2015","issue":null,"author":"Pickup","volume":"38","first-page":"544","unstructured":null,"article-title":"Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2019.107893","key":"10.1016/S2213-8587(25)00335-3_bib50","year":"2019","issue":null,"author":"Nana","volume":"157","first-page":null,"unstructured":null,"article-title":"Flash glucose monitoring: impact on markers of glycaemic control and patient-reported outcomes in individuals with type 1 diabetes mellitus in the real-world setting","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2020.0388","key":"10.1016/S2213-8587(25)00335-3_bib51","year":"2021","issue":null,"author":"Pinsker","volume":"23","first-page":"120","unstructured":null,"article-title":"Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000005722","key":"10.1016/S2213-8587(25)00335-3_bib52","year":"2024","issue":null,"author":"Thorius","volume":"144","first-page":"725","unstructured":null,"article-title":"Glycemic control and risk of congenital malformations in women with type 1 diabetes","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-012-2721-z","key":"10.1016/S2213-8587(25)00335-3_bib53","year":"2012","issue":null,"author":"Glinianaia","volume":"55","first-page":"3193","unstructured":null,"article-title":"HbA1c and birthweight in women with pre-conception type 1 and type 2 diabetes: a population-based cohort study","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000003257","key":"10.1016/S2213-8587(25)00335-3_bib54","year":"2019","issue":null,"author":"Hamel","volume":"133","first-page":"1171","unstructured":null,"article-title":"Intrapartum glucose management in women with gestational diabetes mellitus: a randomized controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1471-2458-12-792","key":"10.1016/S2213-8587(25)00335-3_bib55","year":"2012","issue":null,"author":"Wahabi","volume":"12","first-page":"792","unstructured":null,"article-title":"Pre-pregnancy care for women with pre-gestational diabetes mellitus: a systematic review and meta-analysis","journal-title":"BMC Public Health","doi-asserted-by":"crossref"},{"DOI":"10.1210/clinem/dgab769","key":"10.1016/S2213-8587(25)00335-3_bib56","year":"2022","issue":null,"author":"Lemaitre","volume":"107","first-page":"e1117","unstructured":null,"article-title":"Association between HbA1c levels on adverse pregnancy outcomes during pregnancy in patients with type 1 diabetes","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0073","key":"10.1016/S2213-8587(25)00335-3_bib58","year":"2021","issue":null,"author":"Tundidor","volume":"23","first-page":"710","unstructured":null,"article-title":"Continuous glucose monitoring time-in-range and HbA1c targets in pregnant women with type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1210/endrev/bnac022","key":"10.1016/S2213-8587(25)00335-3_bib59","year":"2023","issue":null,"author":"Phillip","volume":"44","first-page":"254","unstructured":null,"article-title":"Consensus recommendations for the use of automated insulin delivery (AID) technologies in clinical practice","journal-title":"Endocr Rev","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.14273","key":"10.1016/S2213-8587(25)00335-3_bib60","year":"2021","issue":null,"author":"Leelarathna","volume":"23","first-page":"655","unstructured":null,"article-title":"Hybrid closed-loop therapy: where are we in 2021?","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.7573/dic.2021-9-13","key":"10.1016/S2213-8587(25)00335-3_bib61","year":"2022","issue":null,"author":"Kluemper","volume":"11","first-page":"2021","unstructured":null,"article-title":"Diabetes: the role of continuous glucose monitoring","journal-title":"Drugs Context","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-021-05391-w","key":"10.1016/S2213-8587(25)00335-3_bib62","year":"2021","issue":null,"author":"Boughton","volume":"64","first-page":"1007","unstructured":null,"article-title":"New closed-loop insulin systems","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc10-1113","key":"10.1016/S2213-8587(25)00335-3_bib63","year":"2010","issue":null,"author":"Murphy","volume":"33","first-page":"2514","unstructured":null,"article-title":"Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc09-1585","key":"10.1016/S2213-8587(25)00335-3_bib64","year":"2010","issue":null,"author":"Tripathi","volume":"33","first-page":"586","unstructured":null,"article-title":"Preconception counseling in women with diabetes: a population-based study in the north of England","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib65","year":"2025","issue":null,"author":"Rizos","volume":"27","first-page":"537","unstructured":null,"article-title":"Continuous glucose monitoring in type 1 diabetes, type 2 diabetes, and diabetes during pregnancy: a systematic review with meta-analysis of randomized controlled trials","journal-title":"Diabetes Technol Ther","doi-asserted-by":null},{"DOI":"10.1111/dme.14046","key":"10.1016/S2213-8587(25)00335-3_bib66","year":"2019","issue":null,"author":"Murphy","volume":"36","first-page":"1652","unstructured":null,"article-title":"Modelling potential cost savings from use of real-time continuous glucose monitoring in pregnant women with type 1 diabetes","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajogmf.2024.101413","key":"10.1016/S2213-8587(25)00335-3_bib67","year":"2024","issue":null,"author":"Diab","volume":"6","first-page":null,"unstructured":null,"article-title":"Continuous glucose monitoring vs. self-monitoring in pregnant individuals with type 1 diabetes: an economic analysis","journal-title":"Am J Obstet Gynecol MFM","doi-asserted-by":"crossref"},{"DOI":"10.9778/cmajo.20200128","key":"10.1016/S2213-8587(25)00335-3_bib68","year":"2021","issue":null,"author":"Ahmed","volume":"9","first-page":"e627","unstructured":null,"article-title":"The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial","journal-title":"CMAJ Open","doi-asserted-by":"crossref"},{"DOI":"10.1111/ajo.13581","key":"10.1016/S2213-8587(25)00335-3_bib69","year":"2023","issue":null,"author":"Sekhon","volume":"63","first-page":"146","unstructured":null,"article-title":"Continuous glucose monitoring: a cost-effective tool to reduce pre-term birth rates in women with type one diabetes","journal-title":"Aust N Z J Obstet Gynaecol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2303911","key":"10.1016/S2213-8587(25)00335-3_bib70","year":"2023","issue":null,"author":"Lee","volume":"389","first-page":"1566","unstructured":null,"article-title":"Automated insulin delivery in women with pregnancy complicated by type 1 diabetes","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(24)00089-5","key":"10.1016/S2213-8587(25)00335-3_bib71","year":"2024","issue":null,"author":"Benhalima","volume":"12","first-page":"390","unstructured":null,"article-title":"Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2025.19578","key":"10.1016/S2213-8587(25)00335-3_bib72","year":"2025","issue":null,"author":"Donovan","volume":null,"first-page":null,"unstructured":null,"article-title":"Closed-loop insulin delivery in type 1 diabetes in pregnancy: the CIRCUIT randomized clinical trial","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2018.0060","key":"10.1016/S2213-8587(25)00335-3_bib73","year":"2018","issue":null,"author":"Stewart","volume":"20","first-page":"501","unstructured":null,"article-title":"Adaptability of closed loop during labor, delivery, and postpartum: a secondary analysis of data from two randomized crossover trials in type 1 diabetes pregnancy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc24-1320","key":"10.1016/S2213-8587(25)00335-3_bib74","year":"2024","issue":null,"author":"Beunen","volume":"47","first-page":"2002","unstructured":null,"article-title":"Advanced hybrid closed-loop therapy compared with standard insulin therapy intrapartum and early postpartum in women with type 1 diabetes: a secondary observational analysis from the CRISTAL randomized controlled trial","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2024.0012","key":"10.1016/S2213-8587(25)00335-3_bib75","year":"2024","issue":null,"author":"Polsky","volume":"26","first-page":"547","unstructured":null,"article-title":"Randomized trial of assisted hybrid closed-loop therapy versus sensor-augmented pump therapy in pregnancy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc23-0882","key":"10.1016/S2213-8587(25)00335-3_bib76","year":"2023","issue":null,"author":"Donovan","volume":"46","first-page":"2258","unstructured":null,"article-title":"A randomized trial of closed-loop insulin delivery postpartum in type 1 diabetes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib78","year":"2025","issue":"suppl 1","author":"Donovan","volume":"74","first-page":null,"unstructured":null,"article-title":"2084-LB: a randomized multicenter trial of hybrid closed-loop insulin therapy with Control-IQ technology in type 1 diabetes in pregnancy","journal-title":"Diabetes","doi-asserted-by":null},{"DOI":"10.1016/S2213-8587(24)00340-1","key":"10.1016/S2213-8587(25)00335-3_bib77","year":"2025","issue":null,"author":"Lee","volume":"13","first-page":"210","unstructured":null,"article-title":"Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib79","year":"2025","issue":null,"author":"Benhalima","volume":null,"first-page":null,"unstructured":null,"article-title":"Automated insulin delivery in pregnancies complicated by tpe 1 diabetes","journal-title":"J Diabetes Sci Technol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib80","year":"2022","issue":"suppl 1","author":"Okigbo","volume":"71","first-page":null,"unstructured":null,"article-title":"1053-P: prevalence, predictors, and consequences of unplanned pregnancy in women with preexisting diabetes","journal-title":"Diabetes","doi-asserted-by":null},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib81","year":"2019","issue":null,"author":"Jones","volume":"5","first-page":null,"unstructured":null,"article-title":"Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1016/j.diabres.2022.109192","key":"10.1016/S2213-8587(25)00335-3_bib82","year":"2022","issue":null,"author":"Chang","volume":"184","first-page":null,"unstructured":null,"article-title":"Effects of continuous glucose monitoring on maternal and neonatal outcomes in perinatal women with diabetes: a systematic review and meta-analysis of randomized controlled trials","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jcjd.2017.10.038","key":"10.1016/S2213-8587(25)00335-3_bib83","year":"2018","issue":"suppl 1","author":"Feig","volume":"42","first-page":"s255","unstructured":null,"article-title":"Diabetes and pregnancy","journal-title":"Can J Diabetes","doi-asserted-by":"crossref"},{"DOI":"10.1530/EJE-17-0804","key":"10.1016/S2213-8587(25)00335-3_bib84","year":"2018","issue":null,"author":"Rys","volume":"178","first-page":"545","unstructured":null,"article-title":"Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies","journal-title":"Eur J Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2020.108628","key":"10.1016/S2213-8587(25)00335-3_bib85","year":"2021","issue":null,"author":"Żurawska-Kliś","volume":"172","first-page":null,"unstructured":null,"article-title":"Continuous subcutaneous insulin infusion does not correspond with pregnancy outcomes despite better glycemic control as compared to multiple daily injections in type 1 diabetes—significance of pregnancy planning and prepregnancy HbA1c","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1177/1932296820972123","key":"10.1016/S2213-8587(25)00335-3_bib86","year":"2020","issue":null,"author":"Levy","volume":"15","first-page":"1297","unstructured":null,"article-title":"Changes in device uptake and glycemic control among pregnant women with type 1 diabetes: data from the T1D exchange","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1002/14651858.CD005542.pub2","key":"10.1016/S2213-8587(25)00335-3_bib87","year":"2007","issue":null,"author":"Farrar","volume":"3","first-page":null,"unstructured":null,"article-title":"Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-014-3163-6","key":"10.1016/S2213-8587(25)00335-3_bib88","year":"2014","issue":null,"author":"Kallas-Koeman","volume":"57","first-page":"681","unstructured":null,"article-title":"Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc23-1281","key":"10.1016/S2213-8587(25)00335-3_bib89","year":"2024","issue":null,"author":"Thorius","volume":"47","first-page":"384","unstructured":null,"article-title":"Fetal overgrowth and preterm delivery in women with type 1 diabetes using insulin pumps or multiple daily injections: a post hoc analysis of the EVOLVE study cohort","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-022-05864-6","key":"10.1016/S2213-8587(25)00335-3_bib90","year":"2023","issue":null,"author":"Thorius","volume":"66","first-page":"826","unstructured":null,"article-title":"Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.13861","key":"10.1016/S2213-8587(25)00335-3_bib91","year":"2019","issue":null,"author":"Hauffe","volume":"36","first-page":"158","unstructured":null,"article-title":"Higher rates of large-for-gestational-age newborns mediated by excess maternal weight gain in pregnancies with type 1 diabetes and use of continuous subcutaneous insulin infusion vs multiple dose insulin injection","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2022.109854","key":"10.1016/S2213-8587(25)00335-3_bib92","year":"2022","issue":null,"author":"Wang","volume":"187","first-page":null,"unstructured":null,"article-title":"Associations of insulin pump and continuous glucose monitoring use with pregnancy-related outcomes in women with type 1 diabetes","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968231186626","key":"10.1016/S2213-8587(25)00335-3_bib93","year":"2023","issue":null,"author":"Fisher","volume":"17","first-page":"1337","unstructured":null,"article-title":"Continuous subcutaneous infusion versus multiple daily injections of insulin for pregestational diabetes in pregnancy: a systematic review and meta-analysis","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc18-1437","key":"10.1016/S2213-8587(25)00335-3_bib94","year":"2018","issue":null,"author":"Feig","volume":"41","first-page":"2471","unstructured":null,"article-title":"Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.3109/14767058.2013.837444","key":"10.1016/S2213-8587(25)00335-3_bib95","year":"2014","issue":null,"author":"Mathiesen","volume":"27","first-page":"724","unstructured":null,"article-title":"Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes","journal-title":"J Matern Fetal Neonatal Med","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0112","key":"10.1016/S2213-8587(25)00335-3_bib96","year":"2021","issue":null,"author":"O'Malley","volume":"23","first-page":"807","unstructured":null,"article-title":"Longitudinal observation of insulin use and glucose sensor metrics in pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps: the LOIS-P study","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2017.0030","key":"10.1016/S2213-8587(25)00335-3_bib97","year":"2017","issue":null,"author":"Gómez","volume":"19","first-page":"417","unstructured":null,"article-title":"Maternal–fetal outcomes in 34 pregnant women with type 1 diabetes in sensor-augmented insulin pump therapy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-021-05589-y","key":"10.1016/S2213-8587(25)00335-3_bib98","year":"2021","issue":null,"author":"Benhalima","volume":"64","first-page":"2725","unstructured":null,"article-title":"Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00592-023-02080-5","key":"10.1016/S2213-8587(25)00335-3_bib99","year":"2023","issue":null,"author":"Roberto","volume":"60","first-page":"1283","unstructured":null,"article-title":"Sensor augmented pump therapy with predictive suspension function for low glucose levels reduces time in hypoglycaemia in pregnant women with type 1 diabetes","journal-title":"Acta Diabetol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12884-022-04543-z","key":"10.1016/S2213-8587(25)00335-3_bib100","year":"2022","issue":null,"author":"Lee","volume":"22","first-page":"282","unstructured":null,"article-title":"AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial—study protocol","journal-title":"BMC Pregnancy Childbirth","doi-asserted-by":"crossref"},{"DOI":"10.3310/WCHZ4201","key":"10.1016/S2213-8587(25)00335-3_bib101","year":"2024","issue":null,"author":"Lee","volume":"11","first-page":"1","unstructured":null,"article-title":"Automated closed-loop insulin delivery for the management of type 1 diabetes during pregnancy: the AiDAPT RCT","journal-title":"Efficacy and Mechanism Evaluation","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2023.0323","key":"10.1016/S2213-8587(25)00335-3_bib102","year":"2023","issue":null,"author":"Lawton","volume":"25","first-page":"845","unstructured":null,"article-title":"Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12884-023-05481-0","key":"10.1016/S2213-8587(25)00335-3_bib103","year":"2023","issue":null,"author":"Beunen","volume":"23","first-page":"180","unstructured":null,"article-title":"Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial—study protocol","journal-title":"BMC Pregnancy Childbirth","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib104","year":"2024","issue":null,"author":"Quirós","volume":"26","first-page":"596","unstructured":null,"article-title":"Real-world evidence of off-label use of commercially automated insulin delivery systems compared to multiple daily insulin injections in pregnancies complicated by type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":null},{"DOI":"10.1016/j.eclinm.2025.103106","key":"10.1016/S2213-8587(25)00335-3_bib105","year":"2025","issue":null,"author":"Azahaf","volume":"81","first-page":null,"unstructured":null,"article-title":"Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial","journal-title":"eClinicalMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eprac.2025.01.005","key":"10.1016/S2213-8587(25)00335-3_bib106","year":"2025","issue":null,"author":"Buschur","volume":"31","first-page":"494","unstructured":null,"article-title":"Mixed methods randomized controlled trial comparing quality of life for pregnant women with type 1 diabetes using hybrid closed-loop to sensor-augmented pump therapy","journal-title":"Endocr Pract","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2022.0540","key":"10.1016/S2213-8587(25)00335-3_bib107","year":"2023","issue":null,"author":"Szmuilowicz","volume":"25","first-page":"363","unstructured":null,"article-title":"Expert guidance on off-label use of hybrid closed-loop therapy in pregnancies complicated by diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib108","year":"2024","issue":null,"author":"Nandam","volume":"16","first-page":null,"unstructured":null,"article-title":"Tandem T:Slim X2 insulin pump use in clinical practice among pregnant individuals with type 1 diabetes: a retrospective observational cohort study","journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.1007/s00592-025-02469-4","key":"10.1016/S2213-8587(25)00335-3_bib109","year":"2025","issue":null,"author":"Brigham","volume":"62","first-page":"1439","unstructured":null,"article-title":"Case series of a hybrid closed loop therapy system used in pregnancy","journal-title":"Acta Diabetol","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968241266850","key":"10.1016/S2213-8587(25)00335-3_bib110","year":"2024","issue":null,"author":"Klein","volume":"18","first-page":"1263","unstructured":null,"article-title":"Case series of use of an automated insulin delivery system during hospital admission for labor and delivery","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.17925/EE.2024.20.2.14","key":"10.1016/S2213-8587(25)00335-3_bib111","year":"2024","issue":null,"author":"Chillakanti","volume":"20","first-page":"110","unstructured":null,"article-title":"Use of automated insulin delivery in pregnancies complicated by type 1 diabetes","journal-title":"touchREV Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968241279569","key":"10.1016/S2213-8587(25)00335-3_bib112","year":"2024","issue":null,"author":"Sobhani","volume":"18","first-page":"1509","unstructured":null,"article-title":"Use of a Commercially available automated insulin delivery system for the management of type 1 diabetes in pregnancy","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejogrb.2025.113969","key":"10.1016/S2213-8587(25)00335-3_bib113","year":"2025","issue":null,"author":"Tahir","volume":"310","first-page":null,"unstructured":null,"article-title":"Hybrid closed loop insulin therapy versus standard therapy in pregnant women with type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials","journal-title":"Eur J Obstet Gynecol Reprod Biol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00592-025-02446-x","key":"10.1016/S2213-8587(25)00335-3_bib114","year":"2025","issue":null,"author":"Stamati","volume":"62","first-page":"441","unstructured":null,"article-title":"Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis","journal-title":"Acta Diabetol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00592-025-02454-x","key":"10.1016/S2213-8587(25)00335-3_bib115","year":"2025","issue":null,"author":"Yang","volume":"62","first-page":"1325","unstructured":null,"article-title":"Automated insulin delivery in pregnant women with type 1 diabetes: a systematic review and meta-analysis","journal-title":"Acta Diabetol","doi-asserted-by":"crossref"},{"DOI":"10.3390/metabo12111137","key":"10.1016/S2213-8587(25)00335-3_bib116","year":"2022","issue":null,"author":"Munda","volume":"12","first-page":null,"unstructured":null,"article-title":"Carbohydrate intake and closed-loop insulin delivery system during two subsequent pregnancies in type 1 diabetes","journal-title":"Metabolites","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.15086","key":"10.1016/S2213-8587(25)00335-3_bib117","year":"2023","issue":null,"author":"Wang","volume":"40","first-page":null,"unstructured":null,"article-title":"Real-world use of Control-IQ™ technology automated insulin delivery in pregnancy: a case series with qualitative interviews","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2023.110800","key":"10.1016/S2213-8587(25)00335-3_bib118","year":"2023","issue":null,"author":"Albert","volume":"202","first-page":null,"unstructured":null,"article-title":"Off-label use of an automated insulin delivery system in pregnant women with type 1 diabetes","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2025.112454","key":"10.1016/S2213-8587(25)00335-3_bib119","year":"2025","issue":null,"author":"Pham","volume":"228","first-page":null,"unstructured":null,"article-title":"Use of commercially available automated insulin delivery systems in pregnant people with type 1 diabetes","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib120","year":"2025","issue":null,"author":"Sobhani","volume":null,"first-page":null,"unstructured":null,"article-title":"Impact of AID on glycemic profile and maternal/neonatal outcomes in pregnancy: a review of the evidence from observational studies","journal-title":"J Diabetes Sci Technol","doi-asserted-by":null},{"DOI":"10.1177/15209156251379488","key":"10.1016/S2213-8587(25)00335-3_bib121","year":"2025","issue":null,"author":"Quirós","volume":null,"first-page":null,"unstructured":null,"article-title":"A real-world study comparing advanced hybrid closed-loop systems during pregnancy in women with type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.3389/fendo.2021.768639","key":"10.1016/S2213-8587(25)00335-3_bib122","year":"2022","issue":null,"author":"Ozaslan","volume":"12","first-page":null,"unstructured":null,"article-title":"Zone-MPC automated insulin delivery algorithm tuned for pregnancy complicated by type 1 diabetes","journal-title":"Front Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc23-0173","key":"10.1016/S2213-8587(25)00335-3_bib123","year":"2023","issue":null,"author":"Levy","volume":"46","first-page":"1425","unstructured":null,"article-title":"At-home use of a pregnancy-specific zone-MPC closed-loop system for pregnancies complicated by type 1 diabetes: a single-arm, observational multicenter study","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0521","key":"10.1016/S2213-8587(25)00335-3_bib124","year":"2022","issue":null,"author":"Ozaslan","volume":"24","first-page":"471","unstructured":null,"article-title":"Feasibility of closed-loop insulin delivery with a pregnancy-specific zone model predictive control algorithm","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2018.0278","key":"10.1016/S2213-8587(25)00335-3_bib125","year":"2019","issue":null,"author":"Deshpande","volume":"21","first-page":"35","unstructured":null,"article-title":"Design and clinical evaluation of the interoperable artificial pancreas system (iAPS) smartphone app: interoperable components with modular design for progressive artificial pancreas research and development","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1136/bcr-2021-243522","key":"10.1016/S2213-8587(25)00335-3_bib126","year":"2021","issue":null,"author":"Bukhari","volume":"14","first-page":null,"unstructured":null,"article-title":"Open-source automated insulin delivery systems for the management of type 1 diabetes during pregnancy","journal-title":"BMJ Case Rep","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0260","key":"10.1016/S2213-8587(25)00335-3_bib127","year":"2022","issue":null,"author":"Schütz","volume":"24","first-page":"227","unstructured":null,"article-title":"Management of type 1 diabetes mellitus using open-source automated insulin delivery during pregnancy: a case series","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968231169777","key":"10.1016/S2213-8587(25)00335-3_bib128","year":"2023","issue":null,"author":"Sobhani","volume":"17","first-page":"1126","unstructured":null,"article-title":"Use of open-source automated insulin delivery systems in pregnancies with type 1 diabetes","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jcjd.2021.01.006","key":"10.1016/S2213-8587(25)00335-3_bib129","year":"2021","issue":null,"author":"Lemieux","volume":"45","first-page":"804","unstructured":null,"article-title":"Do-it-yourself artificial pancreas system use in pregnant women with type 1 diabetes in a real-world setting: 2 case reports","journal-title":"Can J Diabetes","doi-asserted-by":"crossref"},{"DOI":"10.3310/JYPL3536","key":"10.1016/S2213-8587(25)00335-3_bib130","year":"2024","issue":null,"author":"Asgharzadeh","volume":"28","first-page":"1","unstructured":null,"article-title":"Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling","journal-title":"Health Technol Assess","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00592-024-02284-3","key":"10.1016/S2213-8587(25)00335-3_bib131","year":"2024","issue":null,"author":"Teixeira","volume":"61","first-page":"831","unstructured":null,"article-title":"Efficacy of automated insulin delivery in pregnant women with type 1 diabetes: a meta-analysis and trial sequential analysis of randomized controlled trials","journal-title":"Acta Diabetol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.15357","key":"10.1016/S2213-8587(25)00335-3_bib132","year":"2024","issue":null,"author":"Lei","volume":"26","first-page":"673","unstructured":null,"article-title":"Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-019-4904-3","key":"10.1016/S2213-8587(25)00335-3_bib133","year":"2019","issue":null,"author":"Murphy","volume":"62","first-page":"1123","unstructured":null,"article-title":"Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2022.0479","key":"10.1016/S2213-8587(25)00335-3_bib134","year":"2023","issue":null,"author":"Rankin","volume":"25","first-page":"260","unstructured":null,"article-title":"Rollout of closed-loop technology to pregnant women with type 1 diabetes: healthcare professionals' views about potential challenges and solutions","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.15072","key":"10.1016/S2213-8587(25)00335-3_bib135","year":"2023","issue":null,"author":"Lawton","volume":"40","first-page":null,"unstructured":null,"article-title":"Healthcare professionals' views about how pregnant women can benefit from using a closed-loop system: qualitative study","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-019-4850-0","key":"10.1016/S2213-8587(25)00335-3_bib136","year":"2019","issue":null,"author":"Kristensen","volume":"62","first-page":"1143","unstructured":null,"article-title":"Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2024.01.010","key":"10.1016/S2213-8587(25)00335-3_bib137","year":"2024","issue":null,"author":"Sobhani","volume":"231","first-page":"467","unstructured":null,"article-title":"Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc22-0078","key":"10.1016/S2213-8587(25)00335-3_bib138","year":"2022","issue":null,"author":"Scott","volume":"45","first-page":"1724","unstructured":null,"article-title":"Continuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0194","key":"10.1016/S2213-8587(25)00335-3_bib139","year":"2022","issue":null,"author":"Sibiak","volume":"24","first-page":"42","unstructured":null,"article-title":"Novel continuous glucose monitoring metrics and large-for-gestational-age risk: an exploratory retrospective cohort study in pregnancies with type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2023.0583","key":"10.1016/S2213-8587(25)00335-3_bib140","year":"2024","issue":null,"author":"Søholm","volume":"26","first-page":"536","unstructured":null,"article-title":"Mean glucose and gestational weight gain as predictors of large-for-gestational-age infants in pregnant women with type 1 diabetes using continuous glucose monitoring","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc15-0070","key":"10.1016/S2213-8587(25)00335-3_bib141","year":"2015","issue":null,"author":"Law","volume":"38","first-page":"1319","unstructured":null,"article-title":"Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2024.111088","key":"10.1016/S2213-8587(25)00335-3_bib142","year":"2024","issue":null,"author":"Sibiak","volume":"207","first-page":null,"unstructured":null,"article-title":"Functional analysis of daily glycemic profiles and excessive fetal growth in pregnant patients with well-controlled type 1 diabetes: retrospective cohort","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc19-2527","key":"10.1016/S2213-8587(25)00335-3_bib143","year":"2020","issue":null,"author":"Scott","volume":"43","first-page":"1178","unstructured":null,"article-title":"Continuous glucose monitoring in pregnancy: importance of analyzing temporal profiles to understand clinical outcomes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1210/clinem/dgae291","key":"10.1016/S2213-8587(25)00335-3_bib144","year":"2024","issue":null,"author":"Ling","volume":"109","first-page":"3264","unstructured":null,"article-title":"Basal hyperglycemia contributes more than 50% to time in range in pregnant women with type 1 diabetes","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2024.03.026","key":"10.1016/S2213-8587(25)00335-3_bib145","year":"2024","issue":null,"author":"Battarbee","volume":"231","first-page":"122","unstructured":null,"article-title":"Discrete glucose profiles identified using continuous glucose monitoring data and their association with adverse pregnancy outcomes","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0138","key":"10.1016/S2213-8587(25)00335-3_bib146","year":"2021","issue":null,"author":"Buschur","volume":"23","first-page":"768","unstructured":null,"article-title":"Exploratory analysis of glycemic control and variability over gestation among pregnant women with type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2021.0093","key":"10.1016/S2213-8587(25)00335-3_bib147","year":"2021","issue":null,"author":"Shah","volume":"23","first-page":"783","unstructured":null,"article-title":"Relationship between time-in-range, HbA1c, and the glucose management indicator in pregnancies complicated by type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc20-2360","key":"10.1016/S2213-8587(25)00335-3_bib148","year":"2021","issue":null,"author":"Meek","volume":"44","first-page":"681","unstructured":null,"article-title":"Novel biochemical markers of glycemia to predict pregnancy outcomes in women with type 1 diabetes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc23-0636","key":"10.1016/S2213-8587(25)00335-3_bib149","year":"2024","issue":null,"author":"Sanusi","volume":"47","first-page":"89","unstructured":null,"article-title":"Association of continuous glucose monitoring metrics with pregnancy outcomes in patients with preexisting diabetes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1080/14767058.2022.2050361","key":"10.1016/S2213-8587(25)00335-3_bib150","year":"2022","issue":null,"author":"Tiselko","volume":"35","first-page":"9639","unstructured":null,"article-title":"Glucose variability as the risk factor of preeclampsia in pregnant patients with type 1 diabetes mellitus","journal-title":"J Matern Fetal Neonatal Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib151","year":"2023","issue":null,"author":"Gómez Medina","volume":"200","first-page":null,"unstructured":null,"article-title":"Determination of time in range associated with HbA1c ≤ 6·5% in Latin American pregnant women diagnosed with type 1 diabetes mellitus using an automated insulin delivery system","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":null},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib152","year":"2024","issue":null,"author":"Gómez Medina","volume":"217","first-page":null,"unstructured":null,"article-title":"Time in range and mean glucose cut-off points for reduction of fetal outcomes in pregnant women with type 1 diabetes using automated insulin delivery systems","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":null},{"DOI":"10.1111/dom.14906","key":"10.1016/S2213-8587(25)00335-3_bib153","year":"2023","issue":null,"author":"Rodbard","volume":"25","first-page":"596","unstructured":null,"article-title":"Continuous glucose monitoring metrics (mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.15276","key":"10.1016/S2213-8587(25)00335-3_bib154","year":"2023","issue":null,"author":"Rademaker","volume":"25","first-page":"3798","unstructured":null,"article-title":"Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: a post-hoc analysis of the GlucoMOMS trial","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.1055/s-0038-1629903","key":"10.1016/S2213-8587(25)00335-3_bib155","year":"2018","issue":null,"author":"Dude","volume":"35","first-page":"1119","unstructured":null,"article-title":"Management of diabetes in the intrapartum and postpartum patient","journal-title":"Am J Perinatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.14744","key":"10.1016/S2213-8587(25)00335-3_bib156","year":"2022","issue":null,"author":"Dashora","volume":"39","first-page":null,"unstructured":null,"article-title":"Managing hyperglycaemia during antenatal steroid administration, labour and birth in pregnant women with diabetes—an updated guideline from the Joint British Diabetes Society for Inpatient Care","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.13337","key":"10.1016/S2213-8587(25)00335-3_bib157","year":"2017","issue":null,"author":"Joshi","volume":"34","first-page":"725","unstructured":null,"article-title":"The duration of intrapartum maternal hyperglycaemia predicts neonatal hypoglycaemia in women with pre-existing diabetes","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.13988","key":"10.1016/S2213-8587(25)00335-3_bib158","year":"2019","issue":null,"author":"Yamamoto","volume":"36","first-page":"1046","unstructured":null,"article-title":"Maternal glycaemic control and risk of neonatal hypoglycaemia in type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.14137","key":"10.1016/S2213-8587(25)00335-3_bib159","year":"2020","issue":null,"author":"Yamamoto","volume":"37","first-page":"138","unstructured":null,"article-title":"Severe neonatal hypoglycaemia and intrapartum glycaemic control in pregnancies complicated by type 1, type 2 and gestational diabetes","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/dmrr.2824","key":"10.1016/S2213-8587(25)00335-3_bib160","year":"2017","issue":null,"author":"Yamamoto","volume":"33","first-page":null,"unstructured":null,"article-title":"Large-for-gestational-age (LGA) neonate predicts a 2·5-fold increased odds of neonatal hypoglycaemia in women with type 1 diabetes","journal-title":"Diabetes Metab Res Rev","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.13546","key":"10.1016/S2213-8587(25)00335-3_bib161","year":"2018","issue":null,"author":"Yamamoto","volume":"35","first-page":"173","unstructured":null,"article-title":"Intrapartum glycaemic control and neonatal hypoglycaemia in pregnancies complicated by diabetes: a systematic review","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.13106","key":"10.1016/S2213-8587(25)00335-3_bib162","year":"2016","issue":null,"author":"Drever","volume":"33","first-page":"1253","unstructured":null,"article-title":"Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2023.07.003","key":"10.1016/S2213-8587(25)00335-3_bib163","year":"2023","issue":null,"author":"Wilkie","volume":"229","first-page":"680","unstructured":null,"article-title":"Intrapartum continuous subcutaneous insulin infusion vs intravenous insulin infusion among pregnant individuals with type 1 diabetes mellitus: a randomized controlled trial","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1080/14767058.2021.2004114","key":"10.1016/S2213-8587(25)00335-3_bib164","year":"2022","issue":null,"author":"Wilkie","volume":"35","first-page":"8756","unstructured":null,"article-title":"Comparison of intrapartum glycemic management strategies in pregnant women with type 1 diabetes mellitus","journal-title":"J Matern Fetal Neonatal Med","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc17-0391","key":"10.1016/S2213-8587(25)00335-3_bib165","year":"2017","issue":null,"author":"Padmanabhan","volume":"40","first-page":"1323","unstructured":null,"article-title":"The association of falling insulin requirements with maternal biomarkers and placental dysfunction: a prospective study of women with preexisting diabetes in pregnancy","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc13-1348","key":"10.1016/S2213-8587(25)00335-3_bib166","year":"2014","issue":null,"author":"Achong","volume":"37","first-page":"364","unstructured":null,"article-title":"Peripartum management of glycemia in women with type 1 diabetes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11892-024-01563-1","key":"10.1016/S2213-8587(25)00335-3_bib167","year":"2025","issue":null,"author":"Ringholm","volume":"25","first-page":"7","unstructured":null,"article-title":"Glucose control during labour and delivery in type 1 diabetes—an update on current evidence","journal-title":"Curr Diab Rep","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib168","year":"2024","issue":null,"author":null,"volume":"14","first-page":null,"unstructured":null,"article-title":"Design, rationale and protocol for Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs): an observational cohort study","journal-title":"BMJ Open","doi-asserted-by":null},{"DOI":"10.4158/EP.15.3.187","key":"10.1016/S2213-8587(25)00335-3_bib169","year":"2009","issue":null,"author":"Riviello","volume":"15","first-page":"187","unstructured":null,"article-title":"Breastfeeding and the basal insulin requirement in type 1 diabetic women","journal-title":"Endocr Pract","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00125-018-4794-9","key":"10.1016/S2213-8587(25)00335-3_bib170","year":"2019","issue":null,"author":"Ringholm","volume":"62","first-page":"387","unstructured":null,"article-title":"Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy","journal-title":"Diabetologia","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2019.0280","key":"10.1016/S2213-8587(25)00335-3_bib171","year":"2020","issue":null,"author":"Nørgaard","volume":"22","first-page":"314","unstructured":null,"article-title":"Insulin pump settings during breastfeeding in women with type 1 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11892-020-01315-x","key":"10.1016/S2213-8587(25)00335-3_bib172","year":"2020","issue":null,"author":"Ringholm","volume":"20","first-page":"34","unstructured":null,"article-title":"diabetes management during breastfeeding in women with type 1 diabetes","journal-title":"Curr Diab Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.12993","key":"10.1016/S2213-8587(25)00335-3_bib173","year":"2016","issue":null,"author":"Achong","volume":"33","first-page":"947","unstructured":null,"article-title":"Glycaemic behaviour during breastfeeding in women with type 1 diabetes","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib174","year":"2018","issue":null,"author":"Mackin","volume":"61","first-page":"1081","unstructured":null,"article-title":"Diabetes and pregnancy: national trends over a 15 year period","journal-title":"Diabetologia","doi-asserted-by":null},{"DOI":"10.1186/1471-2393-10-63","key":"10.1016/S2213-8587(25)00335-3_bib175","year":"2010","issue":null,"author":"Wahabi","volume":"10","first-page":"63","unstructured":null,"article-title":"Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis","journal-title":"BMC Pregnancy Childbirth","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41574-024-00973-1","key":"10.1016/S2213-8587(25)00335-3_bib176","year":"2024","issue":null,"author":"Ajjan","volume":"20","first-page":"426","unstructured":null,"article-title":"Continuous glucose monitoring for the routine care of type 2 diabetes mellitus","journal-title":"Nat Rev Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2015.0285","key":"10.1016/S2213-8587(25)00335-3_bib177","year":"2016","issue":null,"author":"Bailey","volume":"18","first-page":"185","unstructured":null,"article-title":"Self-monitoring using continuous glucose monitors with real-time feedback improves exercise adherence in individuals with impaired blood glucose: a pilot study","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc12-2360","key":"10.1016/S2213-8587(25)00335-3_bib178","year":"2013","issue":null,"author":"Secher","volume":"36","first-page":"1877","unstructured":null,"article-title":"The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.a1680","key":"10.1016/S2213-8587(25)00335-3_bib179","year":"2008","issue":null,"author":"Murphy","volume":"337","first-page":null,"unstructured":null,"article-title":"Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.13310","key":"10.1016/S2213-8587(25)00335-3_bib180","year":"2018","issue":null,"author":"Voormolen","volume":"20","first-page":"1894","unstructured":null,"article-title":"Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): a multicentre randomized controlled trial","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000005609","key":"10.1016/S2213-8587(25)00335-3_bib181","year":"2024","issue":null,"author":"Padgett","volume":"144","first-page":"677","unstructured":null,"article-title":"Continuous glucose monitoring for management of type 2 diabetes and perinatal outcomes","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968221124956","key":"10.1016/S2213-8587(25)00335-3_bib182","year":"2022","issue":null,"author":"McLean","volume":"17","first-page":"256","unstructured":null,"article-title":"Feasibility and acceptability of intermittently scanned continuous glucose monitoring for women with type 2 diabetes in pregnancy","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2023.0300","key":"10.1016/S2213-8587(25)00335-3_bib183","year":"2023","issue":null,"author":"McLean","volume":"25","first-page":"836","unstructured":null,"article-title":"Continuous glucose monitoring metrics in high-risk pregnant women with type 2 diabetes","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2025.112111","key":"10.1016/S2213-8587(25)00335-3_bib184","year":"2025","issue":null,"author":"Battelino","volume":"223","first-page":null,"unstructured":null,"article-title":"The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1111/dme.15474","key":"10.1016/S2213-8587(25)00335-3_bib185","year":"2025","issue":null,"author":"Gunabalasingam","volume":"42","first-page":null,"unstructured":null,"article-title":"Interventions in women with type 2 diabetes mellitus in the pre-pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: a systematic review","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1177/19322968221088601","key":"10.1016/S2213-8587(25)00335-3_bib186","year":"2022","issue":null,"author":"Bellido","volume":"17","first-page":"1326","unstructured":null,"article-title":"Expert recommendations for using time-in-range and other continuous glucose monitoring metrics to achieve patient-centered glycemic control in people with diabetes","journal-title":"J Diabetes Sci Technol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2013.10.012","key":"10.1016/S2213-8587(25)00335-3_bib187","year":"2014","issue":null,"author":null,"volume":"103","first-page":"341","unstructured":null,"article-title":"Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.diabres.2021.109050","key":"10.1016/S2213-8587(25)00335-3_bib188","year":"2022","issue":null,"author":"Wang","volume":"183","first-page":null,"unstructured":null,"article-title":"IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's criteria","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)00825-0","key":"10.1016/S2213-8587(25)00335-3_bib189","year":"2024","issue":null,"author":"Sweeting","volume":"404","first-page":"175","unstructured":null,"article-title":"Epidemiology and management of gestational diabetes","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.2337/dbi24-0041","key":"10.1016/S2213-8587(25)00335-3_bib190","year":"2025","issue":null,"author":"Buchanan","volume":"74","first-page":"1037","unstructured":null,"article-title":"What is gestational diabetes—really?","journal-title":"Diabetes","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2021.10404","key":"10.1016/S2213-8587(25)00335-3_bib191","year":"2021","issue":null,"author":"Pillay","volume":"326","first-page":"539","unstructured":null,"article-title":"Screening for gestational diabetes: updated evidence report and systematic review for the US Preventive Services Task Force","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2214956","key":"10.1016/S2213-8587(25)00335-3_bib192","year":"2023","issue":null,"author":"Simmons","volume":"388","first-page":"2132","unstructured":null,"article-title":"Treatment of gestational diabetes mellitus diagnosed early in pregnancy","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pmed.1004087","key":"10.1016/S2213-8587(25)00335-3_bib193","year":"2022","issue":null,"author":"Crowther","volume":"19","first-page":null,"unstructured":null,"article-title":"Tighter or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity: a stepped-wedge, cluster-randomised trial","journal-title":"PLoS Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib194","year":"2023","issue":null,"author":"Hofer","volume":"10","first-page":null,"unstructured":null,"article-title":"Different intensities of glycaemic control for women with gestational diabetes mellitus","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1210/jc.2013-2461","key":"10.1016/S2213-8587(25)00335-3_bib195","year":"2013","issue":null,"author":"Prutsky","volume":"98","first-page":"4319","unstructured":null,"article-title":"Glucose targets in pregnant women with diabetes: a systematic review and meta-analysis","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc11-1687","key":"10.1016/S2213-8587(25)00335-3_bib196","year":"2012","issue":null,"author":"Lowe","volume":"35","first-page":"574","unstructured":null,"article-title":"Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations of maternal A1c and glucose with pregnancy outcomes","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.2147/IJGM.S296316","key":"10.1016/S2213-8587(25)00335-3_bib197","year":"2021","issue":null,"author":"Liu","volume":"14","first-page":"1155","unstructured":null,"article-title":"A review on research progress in the application of glycosylated hemoglobin and glycated albumin in the screening and monitoring of gestational diabetes","journal-title":"Int J Gen Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib198","year":"2017","issue":null,"author":"Sweeting","volume":"102","first-page":"150","unstructured":null,"article-title":"Baseline HbA1c to identify high-risk gestational diabetes: utility in early vs standard gestational diabetes","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":null},{"DOI":"10.1016/j.diabres.2020.108378","key":"10.1016/S2213-8587(25)00335-3_bib199","year":"2020","issue":null,"author":"Immanuel","volume":"168","first-page":null,"unstructured":null,"article-title":"Performance of early pregnancy HbA1c for predicting gestational diabetes mellitus and adverse pregnancy outcomes in obese European women","journal-title":"Diabetes Res Clin Pract","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib200","year":"2017","issue":null,"author":"Raman","volume":"10","first-page":null,"unstructured":null,"article-title":"Different methods and settings for glucose monitoring for gestational diabetes during pregnancy","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1111/dme.14703","key":"10.1016/S2213-8587(25)00335-3_bib201","year":"2022","issue":null,"author":"García-Moreno","volume":"39","first-page":null,"unstructured":null,"article-title":"Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2025.04.010","key":"10.1016/S2213-8587(25)00335-3_bib202","year":"2025","issue":null,"author":"Burk","volume":"233","first-page":"162","unstructured":null,"article-title":"Evidence for improved glucose metrics and perinatal outcomes with continuous glucose monitoring compared to self-monitoring in diabetes during pregnancy","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib203","year":"2025","issue":null,"author":"Linder","volume":null,"first-page":null,"unstructured":null,"article-title":"Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":null},{"DOI":"10.3389/fendo.2023.1174239","key":"10.1016/S2213-8587(25)00335-3_bib204","year":"2023","issue":null,"author":"Lai","volume":"14","first-page":null,"unstructured":null,"article-title":"Effect of continuous glucose monitoring compared with self-monitoring of blood glucose in gestational diabetes patients with HbA1c <6%: a randomized controlled trial","journal-title":"Front Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12020-021-02787-x","key":"10.1016/S2213-8587(25)00335-3_bib205","year":"2021","issue":null,"author":"Shen","volume":"74","first-page":"290","unstructured":null,"article-title":"Identification of maternal continuous glucose monitoring metrics related to newborn birth weight in pregnant women with gestational diabetes","journal-title":"Endocrine","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib206","year":"2023","issue":null,"author":"Liang","volume":"39","first-page":null,"unstructured":null,"article-title":"Continuous glucose monitoring-derived glycemic metrics and adverse pregnancy outcomes among women with gestational diabetes: a prospective cohort study","journal-title":"Lancet Reg Health West Pac","doi-asserted-by":null},{"DOI":"10.1210/jc.2013-4332","key":"10.1016/S2213-8587(25)00335-3_bib207","year":"2014","issue":null,"author":"Yu","volume":"99","first-page":"4674","unstructured":null,"article-title":"Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S2213-8587(25)00335-3_bib208","year":"2016","issue":null,"author":"Wei","volume":"6","first-page":null,"unstructured":null,"article-title":"Effect of a CGMS and SMBG on maternal and neonatal outcomes in gestational diabetes mellitus: a randomized controlled trial","journal-title":"Sci Rep","doi-asserted-by":null},{"DOI":"10.1111/dme.13649","key":"10.1016/S2213-8587(25)00335-3_bib209","year":"2018","issue":null,"author":"Paramasivam","volume":"35","first-page":"1118","unstructured":null,"article-title":"Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial","journal-title":"Diabet Med","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13098-016-0161-5","key":"10.1016/S2213-8587(25)00335-3_bib210","year":"2016","issue":null,"author":"Alfadhli","volume":"8","first-page":"48","unstructured":null,"article-title":"Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes","journal-title":"Diabetol Metab Syndr","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc18-2212","key":"10.1016/S2213-8587(25)00335-3_bib211","year":"2019","issue":null,"author":"Law","volume":"42","first-page":"810","unstructured":null,"article-title":"Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc25-0452","key":"10.1016/S2213-8587(25)00335-3_bib212","year":"2025","issue":null,"author":"Kusinski","volume":null,"first-page":null,"unstructured":null,"article-title":"Continuous glucose monitoring metrics and pregnancy outcomes in women with gestational diabetes mellitus: a secondary analysis of the DiGest trial","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(25)00063-4","key":"10.1016/S2213-8587(25)00335-3_bib213","year":"2025","issue":null,"author":"Amylidi-Mohr","volume":"13","first-page":"591","unstructured":null,"article-title":"Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-8587(25)00093-2","key":"10.1016/S2213-8587(25)00335-3_bib214","year":"2025","issue":null,"author":"Simmons","volume":"13","first-page":"541","unstructured":null,"article-title":"Continuous glucose monitoring in gestational diabetes","journal-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc25-0115","key":"10.1016/S2213-8587(25)00335-3_bib215","year":"2025","issue":null,"author":"Valent","volume":"48","first-page":"1581","unstructured":null,"article-title":"Real-time continuous glucose monitoring in pregnancies with gestational diabetes mellitus: a randomized controlled trial","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000005668","key":"10.1016/S2213-8587(25)00335-3_bib216","year":"2024","issue":null,"author":"Durnwald","volume":"144","first-page":"684","unstructured":null,"article-title":"Continuous glucose monitoring-derived differences in pregnancies with and without adverse perinatal outcomes","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2024.0563","key":"10.1016/S2213-8587(25)00335-3_bib217","year":"2025","issue":null,"author":"Carlson","volume":"27","first-page":"439","unstructured":null,"article-title":"Continuous glucose monitoring-measured glucose levels during oral glucose tolerance testing in pregnancy","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.2337/dc23-2149","key":"10.1016/S2213-8587(25)00335-3_bib218","year":"2024","issue":null,"author":"Durnwald","volume":"47","first-page":"1333","unstructured":null,"article-title":"Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus","journal-title":"Diabetes Care","doi-asserted-by":"crossref"},{"DOI":"10.1089/dia.2024.0080","key":"10.1016/S2213-8587(25)00335-3_bib219","year":"2024","issue":null,"author":"Li","volume":"26","first-page":"787","unstructured":null,"article-title":"Continuous glucose monitoring prediction of gestational diabetes mellitus and perinatal complications","journal-title":"Diabetes Technol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000002501","key":"10.1016/S2213-8587(25)00335-3_bib220","year":"2018","issue":null,"author":null,"volume":"131","first-page":"e49","unstructured":null,"article-title":"ACOG practice bulletin no 190: gestational diabetes mellitus","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S2213858725003353"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Lancet Diabetes & Endocrinology"],"published-print":{"date-parts":[[2026,2]]},"reference-count":219,"published-online":null,"references-count":219,"short-container-title":["The Lancet Diabetes & Endocrinology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/s2213-8587(25)00335-3","is_oa":false,"title":"Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement","updated":"2026-01-11T01:49:12+00:00","published_date":"2025-12-17","best_oa_location":null}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"condition","value":"Gestational Diabetes","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"modality","value":"Automated Insulin Delivery","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"modality","value":"Continuous Glucose Monitoring","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"study_design","value":"Consensus Statement","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"warning","value":"Design classified as a consensus statement rather than a primary study.","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"warning","value":"Only the abstract was available; detailed recommendations and evidence grading are not provided here.","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(25)00335-3","tag_type":"warning","value":"Thresholds for CGM-based diagnosis of gestational diabetes and time-in-range targets for gestational and type 2 diabetes remain unresolved in the text.","value_numeric":null}],"summaries":{"what_studied":"An international consensus statement on the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) for pregnant women with type 1, type 2, or gestational diabetes across preconception, pregnancy, delivery, and postpartum.","key_result":"It recommends CGM during preconception and pregnancy for women with pregestational type 1 diabetes to reduce pregnancy complications and supports AID use in this group across the peripartum period; large randomized trials before and during pregnancy are lacking, and >95% of women with diabetes deliver healthy babies. Appropriate CGM thresholds for diagnosing gestational diabetes and time-in-range targets for routine management of gestational and type 2 diabetes remain undetermined.","limitations":"Large randomized controlled trials of CGM and AID before and during pregnancy are not extensive. CGM-based diagnostic thresholds for gestational diabetes and time-in-range targets for gestational and type 2 diabetes are not yet defined.","practice_takeaway":"Use CGM in women with pregestational type 1 diabetes during preconception and pregnancy to reduce complications, and consider AID across pregnancy, delivery, and postpartum for glycemic management in this group. Do not use CGM thresholds to diagnose gestational diabetes or rely on set time-in-range targets for gestational or type 2 diabetes until they are established."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Automated Insulin Delivery"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Automated Insulin Delivery"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Automated Insulin Delivery"}}}]]

Papers